Degradation kinetics study of cabozantinib by a novel stability-indicating LC method and identification of its major degradation products by LC/TOF-MS and LC–MS/MS

Yakes, 2011, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth, Mol. Cancer Ther., 10, 2298, 10.1158/1535-7163.MCT-11-0264

Viola, 2013, Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer, Future Oncol., 9, 1083, 10.2217/fon.13.128

Smith, 2013, Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial, J. Clin. Oncol., 31, 412, 10.1200/JCO.2012.45.0494

Vaishampayan, 2013, Cabozantinib as a novel therapy for renal cell carcinoma, Curr. Oncol. Rep., 15, 76, 10.1007/s11912-012-0289-x

Nguyen, 2013, Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling, PLoS One, 8, e78881, 10.1371/journal.pone.0078881

ICH, Q1A (R2), 2003

Narayanam, 2014, Critical practical aspects in the application of liquid chromatography–mass spectrometric studies for the characterization of impurities and degradation products, J. Pharm. Biomed. Anal., 87, 191, 10.1016/j.jpba.2013.04.027

Assessment report: Cometriq. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002640/WC500163705.pdf.

Walash, 2011, Stability-indicating HPLC method for determination of naftazone in tablets. Application to degradation kinetics and content uniformity testing, J. Chromatogr. Sci., 49, 495, 10.1093/chrsci/49.7.495

Marques, 2011, Stability-indicating study of the anti-Alzheimer's drug galantamine hydrobromide, J. Pharm. Biomed. Anal., 55, 85, 10.1016/j.jpba.2011.01.022

El-Sayed, 2011, Stability-indicating high performance liquid chromatographic determination of raubasine in its binary mixture with kinetic study of raubasine acid degradation, Talanta, 83, 717, 10.1016/j.talanta.2010.10.012

L.C. Bannen, D.S. Chan, J. Chen, L.E. Dalrymple, T.P. Forsyth, T.P. Huynh, V. Jammalamadaka, R.G. Khoury, J.W. Leahy, M.B. Mac, G. Mann, L.W. Mann, J.M. Nuss, J.J. Parks, C.S. Takeuchi, Y. Wang, W. Xie, c-Met modulators and methods of use. United States patent application publication US 2009/0170896 A1. July 2, 2009.

Wu, 2009, Stability of ricobendazole in aqueous solutions, J. Pharm. Biomed. Anal., 49, 1282, 10.1016/j.jpba.2009.02.032

Jelinska, 2004, The influence of pH, temperature and buffers on the degradation kinetics of cefetamet pivoxil hydrochloride in aqueous solutions, J. Pharm. Biomed. Anal., 35, 1273, 10.1016/j.jpba.2004.03.017

Kim, 2004, Physicochemical properties of 2′-benzoyloxycinnamaldehyde, Int. J. Pharm., 287, 21, 10.1016/j.ijpharm.2004.08.011

Jiang, 2013, Preformulation study of methazolamide for topical ophthalmic delivery: physicochemical properties and degradation kinetics in aqueous solutions, Int. J. Pharm., 448, 390, 10.1016/j.ijpharm.2013.03.018

Hernandez-Luis, 2001, Synthesis and hydrolytic stability studies of albendazole carrier prodrugs, Bioorg. Med. Chem. Lett., 11, 1359, 10.1016/S0960-894X(01)00214-1

Ren, 2011, Kinetics and mechanism of 2,3,5,4′-tetrahydroxystilbene-2-O-beta-d-glycoside (THSG) degradation in aqueous solutions, J. Pharm. Biomed. Anal., 55, 211, 10.1016/j.jpba.2010.12.026